1. Home
  2. PRTC vs TRML Comparison

PRTC vs TRML Comparison

Compare PRTC & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRTC
  • TRML
  • Stock Information
  • Founded
  • PRTC 2015
  • TRML 2021
  • Country
  • PRTC United States
  • TRML United States
  • Employees
  • PRTC 90
  • TRML N/A
  • Industry
  • PRTC Biotechnology: Pharmaceutical Preparations
  • TRML Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRTC Health Care
  • TRML Health Care
  • Exchange
  • PRTC Nasdaq
  • TRML Nasdaq
  • Market Cap
  • PRTC 504.9M
  • TRML 419.1M
  • IPO Year
  • PRTC N/A
  • TRML N/A
  • Fundamental
  • Price
  • PRTC $20.80
  • TRML $27.66
  • Analyst Decision
  • PRTC Buy
  • TRML Strong Buy
  • Analyst Count
  • PRTC 1
  • TRML 3
  • Target Price
  • PRTC $45.00
  • TRML $64.67
  • AVG Volume (30 Days)
  • PRTC 3.4K
  • TRML 202.3K
  • Earning Date
  • PRTC 08-28-2024
  • TRML 11-07-2024
  • Dividend Yield
  • PRTC N/A
  • TRML N/A
  • EPS Growth
  • PRTC N/A
  • TRML N/A
  • EPS
  • PRTC N/A
  • TRML N/A
  • Revenue
  • PRTC $468,000.00
  • TRML N/A
  • Revenue This Year
  • PRTC N/A
  • TRML N/A
  • Revenue Next Year
  • PRTC $139.60
  • TRML N/A
  • P/E Ratio
  • PRTC N/A
  • TRML N/A
  • Revenue Growth
  • PRTC N/A
  • TRML N/A
  • 52 Week Low
  • PRTC $17.08
  • TRML $12.12
  • 52 Week High
  • PRTC $34.00
  • TRML $48.31
  • Technical
  • Relative Strength Index (RSI)
  • PRTC 55.95
  • TRML 58.78
  • Support Level
  • PRTC $20.35
  • TRML $25.10
  • Resistance Level
  • PRTC $20.95
  • TRML $28.35
  • Average True Range (ATR)
  • PRTC 0.62
  • TRML 1.37
  • MACD
  • PRTC 0.10
  • TRML -0.26
  • Stochastic Oscillator
  • PRTC 75.51
  • TRML 57.98

About PRTC PureTech Health plc

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

About TRML Tourmaline Bio Inc.

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Share on Social Networks: